22,135,656
Vote Records
28,570
Companies
12,092
Funds
3,981
Managers

Home › Companies › ATOSSA THERAPEUTICS INC. › 2024-2025

ATOSSA THERAPEUTICS INC. 2024-2025 Proxy Voting Records

At ATOSSA THERAPEUTICS INC.'s shareholder meeting held May 8, 2025, in the 2024-2025 proxy season, 76 asset managers reported how they voted in their SEC Form N-PX filings, covering 535 separate fund positions. Their filings are grouped here into 5 reported items; because filers word the same ballot item differently, that can be more than the number of items on the ballot. On the most widely held item on that ballot — Approval, on a non-binding, advisory basis, of the compensation of the Company's named… — ATOSSA THERAPEUTICS INC.'s filing reports the proposal as approved, with 80% support of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side). Source: ATOSSA THERAPEUTICS INC.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on May 12, 2025.

Download data (CSV): ballot items · votes by manager · column guide.

Compiled from SEC Form N-PX filings and ATOSSA THERAPEUTICS INC.’s Form 8-K, filed May 12, 2025 (Item 5.07 on EDGAR). Page generated November 8, 2026.

  • 5Reported items
  • 76Asset managers
  • 535Fund votes
  • May 8, 2025Meeting date

Results at a glance

Meeting of May 8, 2025: 4 items on ATOSSA THERAPEUTICS INC.’s Form 8-K, filed May 12, 2025: 2 elected · 2 approved.

Material dissent

None.

Material dissent: a director nominee under 80% of the votes cast, say-on-pay under 70%, any other item the board put forward under 80%, or a shareholder proposal with more than 50%, on the company’s own Form 8-K tally. How this is decided

Proxy season: 2024-2025

Explore ATOSSA THERAPEUTICS INC. in the interactive database Compare manager voting policies

Official 2024-2025 meeting results reported by ATOSSA THERAPEUTICS INC.

These tallies are ATOSSA THERAPEUTICS INC.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed May 12, 2025 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.

ATOSSA THERAPEUTICS INC. — official shareholder meeting results, meeting held May 8, 2025
Ballot itemForAgainst AbstainWithheldBroker non-votesSupport (of votes cast)Reported outcomeVoting standard
Elect Director: Steven C. Quay, M.D., Ph.D. 28,401,118---- 4,195,11831,334,563 87%Elected—
Elect Director: Jonathan F. Finn, C.F.A. 30,196,246---- 2,399,99031,334,563 93%Elected—
(ii) Ratification of Independent Auditor The stockholders ratified the selection of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2025 55,807,3886,678,2301,445,181 --0 89%Approved—
(iii) Advisory Vote on Executive Compensation The stockholders approved, on a non-binding, advisory basis, the compensation of the Company's named executive officers 25,638,0546,479,149479,033 --31,334,563 80%Approved—

Source: ATOSSA THERAPEUTICS INC., Form 8-K, filed with the SEC on May 12, 2025 — read the filing on EDGAR.

How asset managers voted at the ATOSSA THERAPEUTICS INC. 2024-2025 meeting

Each item below shows how the 76 asset managers that disclosed a ATOSSA THERAPEUTICS INC. vote in their SEC Form N-PX filings actually voted. Share totals are the shares those managers' funds voted, summed across every fund they report. These are reported items, not a count of the ballot: fund filings describe one ballot item in different words. Two descriptions are shown as one item only on evidence — the same text (or one cut short of the other), the same director nominee, or a match to the same row of ATOSSA THERAPEUTICS INC.’s own Form 8-K tally — never because they merely read alike. A description that could not be joined that way is listed on its own, so one ballot item can appear more than once.

1. Elect Director: Jonathan F. Finn, C.F.A.

Official resultDIRECTOR ELECTIONSReported outcome: Elected

Combines 3 wordings of this item as funds reported it.

93% Majority: yes · of votes cast

FOR 93%
FOR: 30,196,246WITHHELD: 2,399,990
Details: description as filed, official tally, votes by 29 asset managers

Description as filed by funds: Elect Class I Directors: To be elected for terms expiring in 2028. CLASS I NOMINEES: Jonathan F. Finn, C.F.A.

ATOSSA THERAPEUTICS INC.’s own tally for this item (“Elect Director: Jonathan F. Finn, C.F.A.”): 30,196,246 for, 2,399,990 withheld, per its Form 8-K filed May 12, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “At the Annual Meeting, each of the Company's director nominees was elected, a frequency of one year received the majority of votes cast on Proposal 4 and each of the other proposals voted on was approved.”
Support: 93% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 29 asset managers below reported 14,565,521 for, 29,772 withheld.

FOR
FOR: 14,565,521WITHHOLD: 29,772
Largest asset managers voting on “Elect Class I Directors: To be elected for terms expiring in 2028. CLASS I NOMINEES: Jonathan F. Finn, C.F.A.” at ATOSSA THERAPEUTICS INC., 2024-2025
Asset managerForAgainst AbstainWithheldVote
Vanguard6,474,5890 00For
BlackRock4,301,8460 00For
Fidelity2,453,4060 00For
Charles Schwab301,6480 00For
QUANTITATIVE MASTER SERIES LLC210,0820 00For
TIAA170,7330 00For
Lincoln Financial100,1000 00For
Global X74,3220 00For
Pacific Life71,1600 00For
Equitable48,1200 017,380Mixed
AIG/SunAmerica62,3260 00For
Bridge Builder Trust53,7290 00For
Northern Trust51,6070 00For
Voya41,8460 00For
ProShares27,9610 00For
Nationwide24,7910 00For
DWS20,1150 00For
John Hancock19,0200 00For
MASTER INVESTMENT PORTFOLIO14,2880 00For
Victory Capital13,0880 00For
Calvert00 012,392Withhold
T. Rowe Price9,1390 00For
Brinker Capital Destinations Trust6,1300 00For
State Street5,5010 00For
PENN SERIES FUNDS INC4,9000 00For

Showing the 25 largest of 29 asset managers. All 29 are in the interactive database (link above).

2. Elect Director: Steven C. Quay, M.D., Ph.D.

Official resultDIRECTOR ELECTIONSReported outcome: Elected

Combines 3 wordings of this item as funds reported it.

87% Majority: yes · of votes cast

FOR 87%
FOR: 28,401,118WITHHELD: 4,195,118
Details: description as filed, official tally, votes by 29 asset managers

Description as filed by funds: Elect Class I Directors: To be elected for terms expiring in 2028. CLASS I NOMINEES: Steven C. Quay, M.D., Ph.D.

ATOSSA THERAPEUTICS INC.’s own tally for this item (“Elect Director: Steven C. Quay, M.D., Ph.D.”): 28,401,118 for, 4,195,118 withheld, per its Form 8-K filed May 12, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “At the Annual Meeting, each of the Company's director nominees was elected, a frequency of one year received the majority of votes cast on Proposal 4 and each of the other proposals voted on was approved.”
Support: 87% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 29 asset managers below reported 14,582,901 for, 12,392 withheld.

FOR
FOR: 14,582,901WITHHOLD: 12,392
Largest asset managers voting on “Elect Class I Directors: To be elected for terms expiring in 2028. CLASS I NOMINEES: Steven C. Quay, M.D., Ph.” at ATOSSA THERAPEUTICS INC., 2024-2025
Asset managerForAgainst AbstainWithheldVote
Vanguard6,474,5890 00For
BlackRock4,301,8460 00For
Fidelity2,453,4060 00For
Charles Schwab301,6480 00For
QUANTITATIVE MASTER SERIES LLC210,0820 00For
TIAA170,7330 00For
Lincoln Financial100,1000 00For
Global X74,3220 00For
Pacific Life71,1600 00For
Equitable65,5000 00For
AIG/SunAmerica62,3260 00For
Bridge Builder Trust53,7290 00For
Northern Trust51,6070 00For
Voya41,8460 00For
ProShares27,9610 00For
Nationwide24,7910 00For
DWS20,1150 00For
John Hancock19,0200 00For
MASTER INVESTMENT PORTFOLIO14,2880 00For
Victory Capital13,0880 00For
Calvert00 012,392Withhold
T. Rowe Price9,1390 00For
Brinker Capital Destinations Trust6,1300 00For
State Street5,5010 00For
PENN SERIES FUNDS INC4,9000 00For

Showing the 25 largest of 29 asset managers. All 29 are in the interactive database (link above).

3. (iii) Advisory Vote on Executive Compensation The stockholders approved, on a non-binding, advisory basis, the…

Official resultFund totals may overlapSECTION 14A SAY-ON-PAY VOTESReported outcome: Approved

Combines 4 wordings of this item as funds reported it.

80% Approved · of votes cast

FOR 80%AGAINST
FOR: 25,638,054AGAINST: 6,479,149
Details: description as filed, official tally, votes by 76 asset managers

Description as filed by funds: Approval, on a non-binding, advisory basis, of the compensation of the Company's named executive officers.

ATOSSA THERAPEUTICS INC.’s own tally for this item (“(iii) Advisory Vote on Executive Compensation The stockholders approved, on a non-binding, advisory basis, the compensation of the Company's named executive officers by the following votes:”): 25,638,054 for, 6,479,149 against — passed, per its Form 8-K filed May 12, 2025 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “(iii) Advisory Vote on Executive Compensation The stockholders approved, on a non-binding, advisory basis, the compensation of the Company's named executive officers by the following votes:”
Support: 80% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).

Fund voting reports: 29 asset managers voting on “Approval, on a non-binding, advisory basis, of the compensation of the Company's named executive officers.” at ATOSSA THERAPEUTICS INC., 2024-2025
Asset managerForAgainst AbstainWithheldVote
Vanguard6,474,5890 00For
BlackRock4,301,8460 00For
Fidelity2,453,4060 00For
Charles Schwab301,6480 00For
QUANTITATIVE MASTER SERIES LLC210,0820 00For
TIAA170,7330 00For
Lincoln Financial100,1000 00For
Global X074,322 00Against
Pacific Life71,1600 00For
Equitable65,5000 00For
AIG/SunAmerica62,3260 00For
Bridge Builder Trust53,7290 00For
Northern Trust51,6070 00For
Voya41,8460 00For
ProShares27,9610 00For
Nationwide12,50512,286 00Mixed
DWS20,1150 00For
John Hancock19,0200 00For
MASTER INVESTMENT PORTFOLIO14,2880 00For
Victory Capital13,0880 00For
Calvert012,392 00Against
T. Rowe Price9,1390 00For
Brinker Capital Destinations Trust6,1300 00For
State Street5,5010 00For
PENN SERIES FUNDS INC4,9000 00For

Fund voting reports, all 29 managers: 14,496,293 for, 99,000 against. Showing the 25 largest; every one is in the interactive database (link above).

Institutional-manager reports: 58 asset managers voting on “Approval, on a non-binding, advisory basis, of the compensation of the Company's named executive officers.” at ATOSSA THERAPEUTICS INC., 2024-2025
Asset managerForAgainst AbstainWithheldVote
BlackRock3,070,198771 00For
GEODE CAPITAL MANAGEMENT, LLC2,772,2500 00For
State Street1,450,0413,383 00For
Northern Trust496,2650 00For
MELLON INVESTMENTS Corp421,8400 00For
Charles Schwab301,6480 00For
Connor, Clark & Lunn Investment Management Ltd.189,3090 00For
Nuveen170,7330 00For
Vanguard129,2410 00For
Renaissance105,2070 00For
Rhumbline43,38260 00For
JPMorgan59,6250 00For
Invesco053,601 00Against
Voya41,8460 00For
REGIONS FINANCIAL CORP30,0000 00For
WASHINGTON STATE INVESTMENT BOARD026,193 00Against
Neuberger Berman023,700 00Against
John Hancock19,0200 00For
T. Rowe Price18,3980 00For
AllianceBernstein17,3800 00For
NEW YORK STATE COMMON RETIREMENT FUND015,800 00Against
Victory Capital13,0880 00For
Calvert012,392 00Against
Legal & General Investment Management America Inc011,829 00Against
Janney Montgomery Scott LLC010,000 00Against

Institutional-manager reports, all 58 managers: 9,392,763 for, 200,389 against, 44,453 1 year. Showing the 25 largest; every one is in the interactive database (link above).

4. Advisory vote to determine the frequency of future advisory votes on the compensation of the Company's named executive…

No official matchFund totals may overlapSECTION 14A SAY-ON-PAY VOTES

Combines 3 wordings of this item as funds reported it.

99.8% Fund and manager reports combined; may count the same shares twice · no official result

1 YEAR
Details: description as filed, votes by 72 asset managers

Description as filed by funds: Advisory vote to determine the frequency of future advisory votes on the compensation of the Company's named executive officers.

Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice). The figure above is FOR ÷ (FOR + AGAINST + WITHHELD) of the shares these managers voted; abstained and unvoted shares are in neither half, and these managers are a subset of all shareholders, not the meeting result.

Fund voting reports: 29 asset managers voting on “Advisory vote to determine the frequency of future advisory votes on the compensation of the Company's named e” at ATOSSA THERAPEUTICS INC., 2024-2025
Asset managerForAgainst AbstainWithheldVote
Vanguard00 00--
BlackRock00 00--
Fidelity00 00--
Charles Schwab00 00--
QUANTITATIVE MASTER SERIES LLC00 00--
TIAA00 00--
Lincoln Financial00 00--
Global X00 00--
Pacific Life00 00--
Equitable00 00--
AIG/SunAmerica00 00--
Bridge Builder Trust00 00--
Northern Trust00 00--
Voya00 00--
ProShares00 00--
Nationwide00 00--
DWS00 00--
John Hancock00 00--
MASTER INVESTMENT PORTFOLIO00 00--
Victory Capital00 00--
Calvert00 00--
T. Rowe Price00 00--
Brinker Capital Destinations Trust00 00--
State Street00 00--
PENN SERIES FUNDS INC00 00--

Fund voting reports, all 29 managers: 14,595,293 1 year. Showing the 25 largest; every one is in the interactive database (link above).

Institutional-manager reports: 54 asset managers voting on “Advisory vote to determine the frequency of future advisory votes on the compensation of the Company's named e” at ATOSSA THERAPEUTICS INC., 2024-2025
Asset managerForAgainst AbstainWithheldVote
BlackRock00 00--
GEODE CAPITAL MANAGEMENT, LLC00 00--
State Street00 00--
Northern Trust00 00--
MELLON INVESTMENTS Corp00 00--
Charles Schwab00 00--
Connor, Clark & Lunn Investment Management Ltd.00 00--
Nuveen00 00--
Vanguard00 00--
Renaissance00 00--
Rhumbline43,38260 00For
Invesco00 00--
Voya00 00--
REGIONS FINANCIAL CORP00 00--
Neuberger Berman00 00--
John Hancock00 00--
T. Rowe Price00 00--
AllianceBernstein00 00--
NEW YORK STATE COMMON RETIREMENT FUND00 00--
Victory Capital00 00--
Calvert00 00--
Legal & General Investment Management America Inc00 00--
Janney Montgomery Scott LLC00 00--
PRINCIPAL GLOBAL INVESTORS00 00--
MACKENZIE FINANCIAL CORP00 00--

Institutional-manager reports, all 54 managers: 43,382 for, 60 against, 9,504,768 1 year. Showing the 25 largest; every one is in the interactive database (link above).

5. (ii) Ratification of Independent Auditor The stockholders ratified the selection of Ernst & Young LLP as the Company's…

Official resultAUDIT-RELATEDReported outcome: Approved

89% Approved · of votes cast

FOR 89%
FOR: 55,807,388AGAINST: 6,678,230
Details: description as filed, official tally, votes by 29 asset managers

Description as filed by funds: Ratify the selection of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2025.

ATOSSA THERAPEUTICS INC.’s own tally for this item (“(ii) Ratification of Independent Auditor The stockholders ratified the selection of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2025 by the fol”): 55,807,388 for, 6,678,230 against — passed, per its Form 8-K filed May 12, 2025 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “(ii) Ratification of Independent Auditor The stockholders ratified the selection of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2025 by the following votes:”
Support: 89% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 29 asset managers below reported 14,595,293 for.

FOR
FOR: 14,595,293
Largest asset managers voting on “Ratify the selection of Ernst & Young LLP as the Company's independent registered public accounting firm for t” at ATOSSA THERAPEUTICS INC., 2024-2025
Asset managerForAgainst AbstainWithheldVote
Vanguard6,474,5890 00For
BlackRock4,301,8460 00For
Fidelity2,453,4060 00For
Charles Schwab301,6480 00For
QUANTITATIVE MASTER SERIES LLC210,0820 00For
TIAA170,7330 00For
Lincoln Financial100,1000 00For
Global X74,3220 00For
Pacific Life71,1600 00For
Equitable65,5000 00For
AIG/SunAmerica62,3260 00For
Bridge Builder Trust53,7290 00For
Northern Trust51,6070 00For
Voya41,8460 00For
ProShares27,9610 00For
Nationwide24,7910 00For
DWS20,1150 00For
John Hancock19,0200 00For
MASTER INVESTMENT PORTFOLIO14,2880 00For
Victory Capital13,0880 00For
Calvert12,3920 00For
T. Rowe Price9,1390 00For
Brinker Capital Destinations Trust6,1300 00For
State Street5,5010 00For
PENN SERIES FUNDS INC4,9000 00For

Showing the 25 largest of 29 asset managers. All 29 are in the interactive database (link above).

Largest ATOSSA THERAPEUTICS INC. shareholders voting in 2024-2025

Ranked separately for each type of Form N-PX report. An institutional manager can report shares that a fund it advises also reports, so the two tables can list the same shares and are never added together. Each is ranked by the shares voted on the item that the most managers of that type reported, shown as a share of the 129,170,004 shares outstanding at the time of that meeting.

Fund voting reports: top ATOSSA THERAPEUTICS INC. shareholders by shares voted on “Approval, on a non-binding, advisory basis, of the compensation of the Company's named…”, 2024-2025
#Asset manager % of shares outstanding
1Vanguard 5.01%
2BlackRock 3.33%
3Fidelity 1.90%
4Charles Schwab 0.23%
5QUANTITATIVE MASTER SERIES LLC 0.16%
6TIAA 0.13%
7Lincoln Financial 0.08%
8Global X 0.06%
9Pacific Life 0.06%
10Equitable 0.05%
Institutional-manager reports: top ATOSSA THERAPEUTICS INC. shareholders by shares voted on “Approval, on a non-binding, advisory basis, of the compensation of the Company's named…”, 2024-2025
#Asset manager % of shares outstanding
1BlackRock 2.38%
2GEODE CAPITAL MANAGEMENT, LLC 2.15%
3State Street 1.13%
4Northern Trust 0.38%
5MELLON INVESTMENTS Corp 0.33%
6Charles Schwab 0.23%
7Connor, Clark & Lunn Investment Management Ltd. 0.15%
8Nuveen 0.13%
9Vanguard 0.10%
10Renaissance 0.08%

Reported ATOSSA THERAPEUTICS INC. holdings and ownership

As disclosed to the SEC in Form 13F (quarter-end holdings of 30 large managers), Schedules 13D and 13G (beneficial ownership above 5%) and the company’s own proxy statement (DEF 14A). Each row names its form.

ATOSSA THERAPEUTICS INC. holdings and ownership disclosed for the 2024-2025 proxy season
Holder % outstanding Disclosure
Steven C. Quay, M.D., Ph.D. 8.78% DEF14A
BlackRock 7.45% 13F
Vanguard Group 5.10% 13F
CVI Investments, Inc. 4.38% 13G
Geode Capital 2.20% 13F
Renaissance Technologies 1.44% 13F
State Street 1.34% 13F
Heather Rees, CPA (inactive) 1.02% DEF14A
Northern Trust 0.75% 13F
Shu-Chih Chen, Ph.D. 0.45% DEF14A

Percentages above are of 129,170,004 shares outstanding, as reported by ATOSSA THERAPEUTICS INC. on its Form 10-Q dated May 1, 2025 (see the filing on EDGAR). This is the count contemporaneous with the 2024-2025 meeting, not today’s. Each holding is as of its own filing, which may be dated before or after the meeting.

Related

About this page

Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered funds disclose how they voted every proxy and institutional managers disclose their votes on executive pay (say-on-pay, say-on-frequency and golden parachutes), and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from ATOSSA THERAPEUTICS INC.’s 10-Q dated May 1, 2025. This page is a static snapshot rebuilt weekly on November 8, 2026; a live search always shows the current data.

ATOSSA THERAPEUTICS INC. proxy season coverage: 2024-2025 (this page).

Cite this page

proxyvotesnow.com, “ATOSSA THERAPEUTICS (ATOS) 2025 Annual Meeting: Vote Results”, https://proxyvotesnow.com/company/atossa-therapeutics-inc/2025 (version of November 8, 2026). Derived from SEC Form N-PX and Form 8-K filings; tables licensed CC BY 4.0. Licence: CC BY 4.0.